Published in J Virol on October 01, 2005
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc (2010) 0.99
Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers. Iran J Basic Med Sci (2012) 0.89
HPV Vaccines: today and in the Future. J Adolesc Health (2008) 0.88
Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice. Open Virol J (2012) 0.88
The future of vaccines for cervical cancer. Gynecol Oncol (2008) 0.87
Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. Hum Gene Ther (2012) 0.87
Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol J (2009) 0.85
Perspectives for therapeutic HPV vaccine development. J Biomed Sci (2016) 0.85
Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79
Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol (2012) 0.77
The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res (2016) 0.75
Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med (1998) 11.61
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta (1996) 7.79
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Viruses in human cancers. Science (1991) 4.58
Excretion of hepatitis B surface antigen particles from mouse cells transformed with cloned viral DNA. Proc Natl Acad Sci U S A (1980) 3.97
DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet (1993) 2.40
Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med (2003) 2.01
Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis (1995) 1.94
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93
Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer (2002) 1.92
Direct expression of hepatitis B surface antigen in monkey cells from an SV40 vector. DNA (1982) 1.62
DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci U S A (1995) 1.60
Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol Cell Biol (2004) 1.57
Mutational analysis of hepatitis B surface antigen particle assembly and secretion. J Virol (1991) 1.56
Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin Cancer Biol (1999) 1.54
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol (2003) 1.48
Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity (1997) 1.39
A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science (1986) 1.30
A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol (2003) 1.28
Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res (1996) 1.18
Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles. Proc Natl Acad Sci U S A (1988) 1.17
Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther (2004) 1.15
Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A (2004) 1.14
Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst (1997) 1.13
Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine (2004) 1.12
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine (2004) 1.11
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother (2004) 1.04
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer (2000) 1.02
Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J Virol (1994) 1.02
Insertions in the hepatitis B surface antigen. Effect on assembly and secretion of 22-nm particles from mammalian cells. J Mol Biol (1987) 0.98
Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Eur J Immunol (1998) 0.94
Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta (2004) 0.93
Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. J Gen Virol (1997) 0.92
Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol (2001) 0.92
Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. Vaccine (2001) 0.92
Immunization with a plasmid encoding a modified hepatitis B surface antigen carrying the receptor binding site for hepatocytes. Vaccine (1999) 0.89
Epitopes of the human malaria parasite P. falciparum carried on the surface of HBsAg particles elicit an immune response against the parasite. Vaccine (1991) 0.88
Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles. J Virol (1990) 0.86
Presentation of the hydrophilic domains of hepatitis C viral E2 envelope glycoprotein on hepatitis B surface antigen particles. J Med Virol (1996) 0.84
The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes. J Immunol (2002) 0.83
Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen. Proc Natl Acad Sci U S A (1996) 0.78
Morphogenesis in skin is governed by discrete sets of differentially expressed microRNAs. Nat Genet (2006) 6.30
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89
Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med (2009) 2.10
Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med (2003) 2.01
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 1.86
ERp57 is essential for efficient folding of glycoproteins sharing common structural domains. EMBO J (2006) 1.73
A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur J Immunol (2008) 1.68
Platelet-derived ERp57 mediates platelet incorporation into a growing thrombus by regulation of the αIIbβ3 integrin. Blood (2013) 1.57
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol (2006) 1.45
Functionally relevant neutrophilia in CD11c diphtheria toxin receptor transgenic mice. Nat Methods (2012) 1.40
Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice. J Immunol (2010) 1.39
Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur J Immunol (2010) 1.38
Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol (2013) 1.37
A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol (2003) 1.28
Dendritic cells control T cell tonic signaling required for responsiveness to foreign antigen. Proc Natl Acad Sci U S A (2010) 1.27
Consequences of ERp57 deletion on oxidative folding of obligate and facultative clients of the calnexin cycle. J Biol Chem (2006) 1.27
RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med (2013) 1.15
Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer (2008) 1.11
Homeostasis of dendritic cells in lymphoid organs is controlled by regulation of their precursors via a feedback loop. Blood (2009) 1.05
Isolation of multiple TT virus genotypes from spleen biopsy tissue from a Hodgkin's disease patient: genome reorganization and diversity in the hypervariable region. J Virol (2004) 1.04
Boosting regulatory T cells limits neuroinflammation in permanent cortical stroke. J Neurosci (2013) 1.02
Foxp3-mediated suppression of CD95L expression confers resistance to activation-induced cell death in regulatory T cells. J Immunol (2011) 0.98
Depletion of dendritic cells enhances innate anti-bacterial host defense through modulation of phagocyte homeostasis. PLoS Pathog (2012) 0.98
Type 2 innate immunity in helminth infection is induced redundantly and acts autonomously following CD11c(+) cell depletion. Infect Immun (2012) 0.97
E7 oncoprotein of novel human papillomavirus type 108 lacking the E6 gene induces dysplasia in organotypic keratinocyte cultures. J Virol (2009) 0.96
Immature renal dendritic cells recruit regulatory CXCR6(+) invariant natural killer T cells to attenuate crescentic GN. J Am Soc Nephrol (2012) 0.95
Phosphorylation of ectopically expressed L-plastin enhances invasiveness of human melanoma cells. Int J Cancer (2007) 0.95
Propagation of sinusoidal electrical waves along the spinal cord during a fictive motor task. J Neurosci (2009) 0.95
Intestinal cell calcium uptake and the targeted knockout of the 1,25D3-MARRS (membrane-associated, rapid response steroid-binding) receptor/PDIA3/Erp57. J Biol Chem (2010) 0.94
IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions. Cell Rep (2013) 0.90
HLA-DM, HLA-DO and tapasin: functional similarities and differences. Curr Opin Immunol (2002) 0.89
Dickkopf-3, an immune modulator in peripheral CD8 T-cell tolerance. Proc Natl Acad Sci U S A (2012) 0.88
A transporter associated with antigen-processing independent vacuolar pathway for the MHC class I-mediated presentation of endogenous transmembrane proteins. J Immunol (2007) 0.88
Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. J Biol Chem (2007) 0.88
Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice. Open Virol J (2012) 0.88
CD8+ regulatory T cells generated by neonatal recognition of peripheral self-antigen. Proc Natl Acad Sci U S A (2006) 0.88
Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes. Eur J Immunol (2003) 0.83
HPV vaccines: what remains to be done? Interview by Lauren Constable. Expert Rev Vaccines (2011) 0.83
Role of the 1,25D3-MARRS receptor in the 1,25(OH)2D3-stimulated uptake of calcium and phosphate in intestinal cells. Steroids (2012) 0.83
Review of murine dendritic cells: types, location, and development. Methods Mol Biol (2010) 0.82
Increased incidence of squamous cell carcinomas in Mastomys natalensis papillomavirus E6 transgenic mice during two-stage skin carcinogenesis. J Virol (2004) 0.82
Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma. Immunol Lett (2009) 0.81
Mitochondrial structure alteration in human prostate cancer cells upon initial interaction with a chemopreventive agent phenethyl isothiocyanate. Cancer Cell Int (2014) 0.79
In vivo tissue-specific regulation of the human papillomavirus type 18 early promoter by estrogen, progesterone, and their antagonists. Virology (2002) 0.78
Organ-specific cellular requirements for in vivo dendritic cell generation. J Immunol (2011) 0.78
Heparin (GAG-hed) inhibits LCR activity of human papillomavirus type 18 by decreasing AP1 binding. BMC Cancer (2006) 0.77
Highly Sensitive Detection and Genotyping of HPV by PCR Multiplex and Luminex Technology in a Cohort of Colombian Women with Abnormal Cytology. Open Virol J (2011) 0.77
Substantial increase in the frequency of circulating CD4+NKG2D+ T cells in patients with cervical intraepithelial neoplasia grade 1. J Biomed Sci (2013) 0.77
Modern criteria to determine the etiology of human carcinogens. Semin Cancer Biol (2004) 0.77
The 1,25D3 -MARRS receptor/PDIA3/ERp57 and lifespan. J Cell Biochem (2015) 0.76
Corrigendum: Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol (2016) 0.75